Soleno Therapeutics Faces Potential Setback in Vykat Launch Following Patient's Unfortunate Demise, Despite No Direct Link Established
In a significant development for the medical community, Soleno Therapeutics (NASDAQ:SLNO) announced the approval of its drug Vykat (diazoxide choline) to treat patients aged over 4 years with Prader-Willi syndrome (PWS). This approval comes following the announcement of positive statistically significant results for the primary endpoint from the RW period of Study C602 on September 26, 2023.
Vykat, also known as Diazoxide Choline Extended-Release Tablets ("DCCR
Read also:
- Top-Notch Home and Expert Age Spot Remedies
- 'Starting today, registration for the Ayushman Bharat Scheme is available'; announced Delhi's Health Minister, Pankaj Kumar Singh
- Apparition's Significance and its Delivered Messages - as discussed by Sensenmann
- Explored the Popular Health Assessment with a Queue of 100,000 Aspiring Participants - Here's My Unadulterated Opinion
